Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bladder cancer clinical trials.

Seth P Lerner1

  • 1Scott Department of Urology, Baylor College of Medicine, Houston, TX 77030, USA. slerner@bcm.tmc.edu

Urologic Oncology
|July 16, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early Efficacy and Exploratory Biomarker Data of Bel-sar in Patients with Intermediate-risk and High-risk Non-muscle-invasive Bladder Cancer.

European urology open science·2026
Same author

Radiogenomic analysis of muscle-invasive bladder cancer using CT-based texture analysis.

Bladder cancer (Amsterdam, Netherlands)·2026
Same author

Narrative Review of Potential Non-Surgical Treatments for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer.

Journal of clinical medicine·2026
Same author

Cigarette smoke induces FASN-dependent fatty acid metabolic rewiring to drive bladder cancer progression.

Cancer letters·2026
Same author

Leveraging untargeted metabolomics in combination with machine learning to uncover novel insights into bladder cancer.

Cancer & metabolism·2026
Same author

Enfortumab Vedotin plus Pembrolizumab as Perioperative Therapy.

The New England journal of medicine·2026
Same journal

Does size matter? A national analysis of patterns of adjuvant immunotherapy receipt and tumor size-dependent survival in pT3N0M0 clear cell renal cell carcinoma.

Urologic oncology·2026
Same journal

Ipsilateral sampling maintains clinically significant cancer detection and reduces overdiagnosis in PI-RADS 4-5 lesions.

Urologic oncology·2026
Same journal

Testis-sparing surgery for small testicular masses: Functional and oncological outcomes.

Urologic oncology·2026
Same journal

Subcapsular versus total orchiectomy in advanced prostate cancer: A systematic review and meta-analysis of clinical and patient-reported outcomes.

Urologic oncology·2026
Same journal

Featured SUO Fellow: Soum Lokeshwar, MD MBA.

Urologic oncology·2026
Same journal

Automating standardization of prostate cancer biopsy and histopathology reports with privacy-preserving local large language models.

Urologic oncology·2026
See all related articles

Bladder cancer is a common and costly public health issue. This review highlights critical clinical trials research, particularly from the EORTC, addressing management questions for non-muscle invasive and invasive bladder cancer.

Area of Science:

  • Urologic Oncology
  • Cancer Epidemiology

Background:

  • Bladder cancer is a significant public health concern, ranking as the fourth most common cancer in U.S. men and ninth in women.
  • The condition is highly prevalent, with substantial patient numbers globally, and represents the most expensive cancer for diagnosis and treatment.
  • Numerous clinical questions remain, driving a growing number of research initiatives, including those funded by the NIH and industry.

Purpose of the Study:

  • To review the critical role of clinical trials research in addressing key management questions for bladder cancer.
  • To highlight the contributions of the European Organisation for Research and Treatment of Cancer (EORTC) in conducting phase II and large phase III randomized trials.

Main Methods:

  • Review of existing literature and clinical trials data.

Related Experiment Videos

  • Focus on trials addressing non-muscle invasive and invasive bladder cancer management.
  • Emphasis on research conducted by the EORTC.

    • Main Results:

    • The EORTC has been instrumental in conducting significant phase II and phase III randomized trials.
    • These trials have addressed crucial questions in the management of both non-muscle invasive and invasive bladder cancer.
    • The review synthesizes findings from this important body of clinical trials research.

    Conclusions:

    • Clinical trials are essential for advancing the understanding and treatment of bladder cancer.
    • The EORTC has made substantial contributions to bladder cancer clinical trials research.
    • Continued research is vital to address the public health and economic impact of bladder cancer.